A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tofacitinib Impurity 38 - Request Quote

Picture of Tofacitinib Impurity 38

Tofacitinib Impurity 38

SZ CAT No:SZ-T010101
CAS No
NA
Mol.F.
C14H20N6O
Mol.Wt.
288.4
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Tofacitinib Impurity 38 is chemically 3-((3R,4R)-3-(((6-Aminopyrimidin-4-yl)methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile. Tofacitinib Impurity 38 is supplied with detailed characterization data compliant with regulatory guideline. Tofacitinib Impurity 38 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tofacitinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Tofacitinib Impurity 38

Purchase Tofacitinib Impurity 38

Tofacitinib Impurity 38 suppliers

Tofacitinib Impurity 38 manufacturers

Tofacitinib Impurity 38 price

Order Tofacitinib Impurity 38

Enquire Tofacitinib Impurity 38

Tofacitinib Impurity 38 cost

Tofacitinib Impurity 38 Supplier

Tofacitinib Impurity 38 Distributor

Tofacitinib Impurity 38 for Method Validation

Tofacitinib Reference Standard

Tofacitinib Impurity 38 for ANDA Filing

Tofacitinib Impurity 38 for Forced Degradation Studies

Tofacitinib Impurity 38 Identification Standards

Tofacitinib Impurity 38 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,